Takayama, T.; Shimizu, T.; Abu Lila, A.S.; Kanazawa, Y.; Ando, H.; Ishima, Y.; Ishida, T.
Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil®) in C26 Tumor-Bearing Immunocompetent Mice. Pharmaceutics 2020, 12, 990.
https://doi.org/10.3390/pharmaceutics12100990
AMA Style
Takayama T, Shimizu T, Abu Lila AS, Kanazawa Y, Ando H, Ishima Y, Ishida T.
Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil®) in C26 Tumor-Bearing Immunocompetent Mice. Pharmaceutics. 2020; 12(10):990.
https://doi.org/10.3390/pharmaceutics12100990
Chicago/Turabian Style
Takayama, Takuma, Taro Shimizu, Amr S. Abu Lila, Yuki Kanazawa, Hidenori Ando, Yu Ishima, and Tatsuhiro Ishida.
2020. "Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil®) in C26 Tumor-Bearing Immunocompetent Mice" Pharmaceutics 12, no. 10: 990.
https://doi.org/10.3390/pharmaceutics12100990
APA Style
Takayama, T., Shimizu, T., Abu Lila, A. S., Kanazawa, Y., Ando, H., Ishima, Y., & Ishida, T.
(2020). Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil®) in C26 Tumor-Bearing Immunocompetent Mice. Pharmaceutics, 12(10), 990.
https://doi.org/10.3390/pharmaceutics12100990